- Home
- CNTA vs VKTX Comparison
CNTA vs VKTX Comparison
Compare CNTA & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CNTA | VKTX |
|---|---|---|
| Founded | 2020 | 2012 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.8B |
| IPO Year | 2021 | 2015 |
Fundamental Metrics
Financial Performance| Metric | CNTA | VKTX |
|---|---|---|
| Price | $25.65 | $30.31 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 14 |
| Target Price | $38.00 | ★ $87.07 |
| AVG Volume (30 Days) | 1.6M | ★ 3.3M |
| Earning Date | 11-05-2025 | 02-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $15,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 118.88 | N/A |
| 52 Week Low | $9.60 | $18.92 |
| 52 Week High | $30.58 | $43.15 |
Technical Indicators
Market Signals| Indicator | CNTA | VKTX |
|---|---|---|
| Relative Strength Index (RSI) | 60.26 | 38.27 |
| Support Level | $21.50 | $32.42 |
| Resistance Level | $26.63 | $34.99 |
| Average True Range (ATR) | 1.13 | 1.92 |
| MACD | 0.52 | -0.13 |
| Stochastic Oscillator | 81.48 | 12.59 |
Price Performance
Historical ComparisonAbout CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.